Literature DB >> 12481419

Translation initiation in cancer: a novel target for therapy.

Funda Meric1, Kelly K Hunt.   

Abstract

Translation initiation is regulated in response to nutrient availability and mitogenic stimulation and is coupled with cell cycle progression and cell growth. Several alterations in translational control occur in cancer. Variant mRNA sequences can alter the translational efficiency of individual mRNA molecules, which in turn play a role in cancer biology. Changes in the expression or availability of components of the translational machinery and in the activation of translation through signal transduction pathways can lead to more global changes, such as an increase in the overall rate of protein synthesis and translational activation of the mRNA molecules involved in cell growth and proliferation. We review the basic principles of translational control, the alterations encountered in cancer, and selected therapies targeting translation initiation to help elucidate new therapeutic avenues.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12481419

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  43 in total

1.  Inhibitors of protein synthesis identified by a high throughput multiplexed translation screen.

Authors:  Olivia Novac; Anne-Sophie Guenier; Jerry Pelletier
Journal:  Nucleic Acids Res       Date:  2004-02-09       Impact factor: 16.971

2.  Eukaryotic protein synthesis inhibitors identified by comparison of cytotoxicity profiles.

Authors:  Jenny Chan; Shakila N Khan; Isabelle Harvey; William Merrick; Jerry Pelletier
Journal:  RNA       Date:  2004-03       Impact factor: 4.942

3.  Systematic identification and functional screens of uncharacterized proteins associated with eukaryotic ribosomal complexes.

Authors:  Tracey C Fleischer; Connie M Weaver; K Jill McAfee; Jennifer L Jennings; Andrew J Link
Journal:  Genes Dev       Date:  2006-05-15       Impact factor: 11.361

4.  Rapamycin regulates stearoyl CoA desaturase 1 expression in breast cancer.

Authors:  David Luyimbazi; Argun Akcakanat; Priscilla F McAuliffe; Li Zhang; Gopal Singh; Ana Maria Gonzalez-Angulo; Huiqin Chen; Kim-Anh Do; Yuhuan Zheng; Mien-Chie Hung; Gordon B Mills; Funda Meric-Bernstam
Journal:  Mol Cancer Ther       Date:  2010-09-28       Impact factor: 6.261

5.  Translational activation of developmental messenger RNAs during neonatal mouse testis development.

Authors:  Vesna A Chappell; Jonathan T Busada; Brett D Keiper; Christopher B Geyer
Journal:  Biol Reprod       Date:  2013-09-19       Impact factor: 4.285

6.  Diversity in transcriptional start site selection and alternative splicing affects the 5'-UTR of mouse striated muscle myosin transcripts.

Authors:  Briana K Dennehey; Leslie A Leinwand; Kenneth S Krauter
Journal:  J Muscle Res Cell Motil       Date:  2006-07-04       Impact factor: 2.698

Review 7.  Targeted polymeric nanoparticles for cancer gene therapy.

Authors:  Jayoung Kim; David R Wilson; Camila G Zamboni; Jordan J Green
Journal:  J Drug Target       Date:  2015-06-10       Impact factor: 5.121

8.  Secretome of human bone marrow mesenchymal stem cells: an emerging player in lung cancer progression and mechanisms of translation initiation.

Authors:  Oshrat Attar-Schneider; Victoria Zismanov; Liat Drucker; Maya Gottfried
Journal:  Tumour Biol       Date:  2015-10-30

9.  Structure-activity relationship study of 4EGI-1, small molecule eIF4E/eIF4G protein-protein interaction inhibitors.

Authors:  Khuloud Takrouri; Ting Chen; Evangelos Papadopoulos; Rupam Sahoo; Eihab Kabha; Han Chen; Sonia Cantel; Gerhard Wagner; Jose A Halperin; Bertal H Aktas; Michael Chorev
Journal:  Eur J Med Chem       Date:  2014-03-13       Impact factor: 6.514

Review 10.  Rocaglamide, silvestrol and structurally related bioactive compounds from Aglaia species.

Authors:  Li Pan; John L Woodard; David M Lucas; James R Fuchs; A Douglas Kinghorn
Journal:  Nat Prod Rep       Date:  2014-05-02       Impact factor: 13.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.